Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T, Naiki T, Sugiyama Y, Nagai T, Iida K, Noda Y, Shimizu N, Tasaki Y, Mimura Y, Okada T, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Etani T, et al. Among authors: shimizu n. Oncology. 2020;98(12):876-883. doi: 10.1159/000508923. Epub 2020 Aug 28. Oncology. 2020. PMID: 32862183
Efficacy of fosfomycin in the prevention of postoperative infection following transurethral resection of bladder tumor during periods of limited cefazolin, cefotiam, and cefmetazole supply.
Etani T, Asaoka M, Kondo S, Wachino C, Hori K, Shimizu N, Noda Y, Nagai T, Nozaki S, Iida K, Naiki T, Ando R, Kawai N, Yanagita T, Nakamura A, Yasui T. Etani T, et al. Among authors: shimizu n. J Infect Chemother. 2021 Apr;27(4):625-631. doi: 10.1016/j.jiac.2020.11.025. Epub 2020 Dec 10. J Infect Chemother. 2021. PMID: 33309628
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Naiki T, Nagai T, Sugiyama Y, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Isobe T, Matsumoto D, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Naiki T, et al. Among authors: shimizu n. Oncology. 2021;99(10):622-631. doi: 10.1159/000517326. Epub 2021 Jul 20. Oncology. 2021. PMID: 34284409
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Tomiyama N, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Isobe T, et al. Among authors: shimizu n. Int J Clin Oncol. 2022 Jan;27(1):165-174. doi: 10.1007/s10147-021-02046-z. Epub 2021 Oct 11. Int J Clin Oncol. 2022. PMID: 34633579
Comparison of drug susceptibility between Escherichia coli detected in stool cultures of patients undergoing transrectal prostate needle biopsy and Escherichia coli in hospital-wide urine antibiograms.
Etani T, Mogami T, Yamaguchi S, Takeda T, Sugino T, Shimizu N, Noda Y, Nagai T, Nozaki S, Iida K, Naiki T, Ando R, Kawai N, Yasui T. Etani T, et al. Among authors: shimizu n. J Infect Chemother. 2022 Feb;28(2):343-346. doi: 10.1016/j.jiac.2021.10.022. Epub 2021 Nov 5. J Infect Chemother. 2022. PMID: 34750049
3,242 results